Oncogenic role of DDX3 in breast cancer biogenesis

被引:179
|
作者
Botlagunta, M. [1 ]
Vesuna, F. [1 ]
Mironchik, Y. [1 ]
Raman, A. [2 ]
Lisok, A. [1 ]
Winnard, P., Jr. [1 ]
Mukadam, S. [1 ]
Van Diest, P. [3 ]
Chen, J. H. [4 ]
Farabaugh, P.
Patel, A. H. [5 ]
Raman, V. [6 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA
[2] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA
[3] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands
[4] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan
[5] Arvind Patel Inst Virol, Glasgow G11, Lanark, Scotland
[6] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
基金
英国医学研究理事会;
关键词
DDX3; breast cancer; BPDE;
D O I
10.1038/onc.2008.33
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Benzo[a] pyrene diol epoxide (BPDE), the active metabolite of benzo[a] pyrene present in tobacco smoke, is a major cancer-causing compound. To evaluate the effects of BPDE on human breast epithelial cells, we exposed an immortalized human breast cell line, MCF 10A, to BPDE and characterized the gene expression pattern. Of the differential genes expressed, we found consistent activation of DDX3, a member of the DEAD box RNA helicase family. Overexpression of DDX3 in MCF 10A cells induced an epithelial-mesenchymal- like transformation, exhibited increased motility and invasive properties, and formed colonies in soft-agar assays. Besides the altered phenotype, MCF 10A-DDX3 cells repressed E-cadherin expression as demonstrated by both immunoblots and by E-cadherin promoter-reporter assays. In addition, an in vivo association of DDX3 and the E-cadherin promoter was demonstrated by chromatin immunoprecipitation assays. Collectively, these results demonstrate that the activation of DDX3 by BPDE, can promote growth, proliferation and neoplastic transformation of breast epithelial cells.
引用
收藏
页码:3912 / 3922
页数:11
相关论文
共 50 条
  • [31] Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer
    van Voss, Manse R. Heerma
    Vesuna, Farhad
    Trumpi, Kari
    Brilliant, Justin
    Kodach, Liudmila L.
    Morsink, Folkert H. M.
    Offerhaus, G. Johan A.
    Buerger, Horst
    van der Wall, Elsken
    van Diest, Paul J.
    Raman, Venu
    CANCER RESEARCH, 2015, 75
  • [32] Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment
    van Voss, M. R. Heerma
    Vesuna, F.
    Bol, G. M.
    Afzal, J.
    Tantravedi, S.
    Bergman, Y.
    Kammers, K.
    Lehar, M.
    Malek, R.
    Ballew, M.
    ter Hoeve, N.
    Abou, D.
    Thorek, D.
    Berlinicke, C.
    Yazdankhah, M.
    Sinha, D.
    Le, A.
    Abrahams, R.
    Tran, P. T.
    van Diest, P. J.
    Raman, V.
    ONCOGENE, 2018, 37 (01) : 63 - 74
  • [33] DDX3 participates in miRNA biogenesis and RNA interference through translational control of PACT and interaction with AGO2
    Lai, Ming-Chih
    Yu, Yen-Ling
    Chen, Chiao-Nung
    Yu, Jau-Song
    Hung, Hsin-Yuan
    Chan, Shih-Peng
    FEBS OPEN BIO, 2025, 15 (01): : 180 - 195
  • [34] DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer
    Su, Chia-Yi
    Lin, Tsung-Chieh
    Lin, Yuan-Feng
    Chen, Ming-Huang
    Lee, Chien-Hsin
    Wang, Hsuan-Yao
    Lee, Yu-Chieh
    Liu, Yu-Peng
    Chen, Chi-Long
    Hsiao, Michael
    ONCOTARGET, 2015, 6 (21) : 18602 - 18612
  • [35] Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment
    M R Heerma van Voss
    F Vesuna
    G M Bol
    J Afzal
    S Tantravedi
    Y Bergman
    K Kammers
    M Lehar
    R Malek
    M Ballew
    N ter Hoeve
    D Abou
    D Thorek
    C Berlinicke
    M Yazdankhah
    D Sinha
    A Le
    R Abrahams
    P T Tran
    P J van Diest
    V Raman
    Oncogene, 2018, 37 : 63 - 74
  • [36] Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer
    van Voss, Marise R. Heerma
    Brilliant, Justin D.
    Vesuna, Farhad
    Bol, Guus M.
    van der Wall, Elsken
    van Diest, Paul J.
    Raman, Venu
    MEDICAL ONCOLOGY, 2017, 34 (03)
  • [37] Differential Expression of DDX3 and microRNAs in Response to Hormone and Cisplatin Against Cervical Cancer
    Botlagunta, Mahendran
    Khatri, Karishma
    Devi B, Madhavi
    Doneti, Ravinder
    Pasha, Akbar
    Pawar, Smita C.
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2022, 6 (04): : 307 - 316
  • [38] Post-transcriptional regulation of androgen receptor by DDX3 in prostate cancer progression
    Vellky, Jordan E.
    Ricke, William
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer
    van Voss, Marise R. Heerma
    Vesuna, Farhad
    Trumpi, Kari
    Brilliant, Justin
    Berlinicke, Cynthia
    de Leng, Wendy
    Kranenburg, Onno
    Offerhaus, Johan G.
    Buerger, Horst
    van der Wall, Elsken
    van Diest, Paul J.
    Raman, Venu
    ONCOTARGET, 2015, 6 (29) : 28312 - 28326
  • [40] Targeting the Human DEAD-Box RNA Helicase, DDX3, as a Novel Strategy to Inhibit Aggressive Breast Cancer Metastasis
    de Victoria, Aliana Lopez
    Koculi, Eda
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 225A - 225A